Myasthenia Gravis
FDA grants priority review to nipocalimab for myasthenia gravis
The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized myasthenia gravis who are antibody positive, according to the manufacturer.
IV nipocalimab reduces disease expression in generalized myasthenia gravis
Treatment with IV nipocalimab was safe and led to significant reductions in disease expression at 24 weeks in adolescents with generalized myasthenia gravis, according to data presented at AANEM.
Uplizna treatment shows greater improvement in myasthenia gravis compared with placebo
IV administration of Uplizna was safe and shown to be more efficacious for those with generalized myasthenia gravis compared with placebo at week 26, according to a presentation from AANEM.
Algorithm for myasthenia gravis testing via telehealth feasible
ORLANDO, Fla. — An algorithm for standardizing myasthenia gravis diagnosis during telehealth is feasible, but it requires additional testing and validation, according to researchers.
Phase 3 clinical trial commences for oral myasthenia gravis treatment
The first patient has been dosed in a phase 3 clinical trial of oral cladribine for the treatment of generalized myasthenia gravis, according to the manufacturer.
FDA approves IND application for Eque-cel T-cell therapy in SLE, lupus nephritis
The FDA has approved an investigational new drug application for Eque-cel, an autologous T-cell injection, in patients with systemic lupus erythematosus and lupus nephritis, according to a press release from the manufacturer.
VIDEO: Antibiotics linked to exacerbation of myasthenia gravis
DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of Neurology annual meeting.
Patient with lupus treated with KYV-101 CAR T-cell therapy relapses after 5 months
A patient with lupus nephritis treated with KYV-101, a chimeric antigen receptor T-cell immunotherapy, saw their disease return 5 months after initially showing a response to the treatment, according to the manufacturer.
Black, Hispanic individuals have more negative experience, concerns in myasthenia gravis
DENVER — Experiences and concerns about treatment, diagnosis, care, cost and quality of life among Black and Hispanic patients with myasthenia gravis were more negative compared with their Asian and white counterparts, according to research.
Adverse mental health linked to uncontrolled symptoms of myasthenia gravis
DENVER — Uncontrolled generalized myasthenia negatively affects patients’ mental health, which in turn negatively impacts their physical symptoms, according to a poster presentation at the American Academy of Neurology annual meeting.